Niagen Bioscience (NAGE) stock price is $2.51, up 0.40% on the day, as of Oct 20, 2026. It has a market cap of $198.31Mn and a P/E ratio of 12.44, and is classified in the Personal Care Products industry (Consumer Staples sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap198.31 Mn
P/E12.44
P/S1.54
Div. Yield0.00
Revenue Growth (1y) (Qtr)-4.28
Add ratio to table…
About
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. The company focuses on the science of nicotinamide adenine dinucleotide (NAD+) and its role in cellular metabolism. It develops and commercializes products that aim to increase NAD+ levels to support health and longevity. Its core offerings include the proprietary ingredient Niagen and the finished supplement Tru Niagen.
<parameter>Niagen Bioscience generates revenue primarily from…
Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. The company focuses on the science of nicotinamide adenine dinucleotide (NAD+) and its role in cellular metabolism. It develops and commercializes products that aim to increase NAD+ levels to support health and longevity. Its core offerings include the proprietary ingredient Niagen and the finished supplement Tru Niagen.
<parameter>Niagen Bioscience generates revenue primarily from the sale of Tru Niagen to consumers through direct to consumer channels and through retail and online distributors. The company also sells its Niagen ingredient in food grade and pharmaceutical grade forms to manufacturers of dietary supplements and foods and to U. S. FDA registered 503B outsourcing facilities and compounding pharmacies for use in compounded formulations. Additionally, revenue is derived from the analytical reference standards and services segment which supplies research and quality control products to various industries. The company has reported steady revenue growth driven by increasing consumer awareness of NAD+ benefits and expanding international distribution. The company’s revenue streams are diversified across consumer products, ingredient sales, and laboratory services, reducing reliance on any single source.</parameter> The company operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.
Consumer Products: This segment develops, markets, and distributes the finished dietary supplement Tru Niagen. It sells the product directly to consumers via its proprietary online platform and through third party online marketplaces such as Amazon. The segment also works with strategic distribution partners to reach specialty retailers and authorized health practitioners in the United States and internationally.
Ingredients: This segment produces and supplies food grade Niagen as a raw material to manufacturers of consumer products. It also provides pharmaceutical grade Niagen to U. S. FDA registered 503B outsourcing facilities and compounding pharmacies for compounding activities. The segment supports its customers with technical assistance, regulatory guidance, and supply chain management to ensure successful incorporation of Niagen into final products.
Analytical Reference Standards and Services: This segment provides research and quality control products, including highly characterized phytochemicals and natural products. It offers related testing services to customers in the dietary supplement, food and beverage, cosmetic, pharmaceutical, and life sciences industries. The segment helps clients verify the purity and identity of raw materials and finished products to meet quality and regulatory requirements.
Niagen Bioscience holds a leading position in the emerging NAD+ market, supported by a robust patent portfolio and extensive research collaborations with academic institutions and healthcare organizations. The company’s competitive advantages include its scientific credibility, proprietary ingredient technology, and global distribution network, which differentiate it from other NAD+ supplement providers. It also benefits from a strong scientific advisory board that includes Nobel laureates and experts from leading research institutions. These strengths enable Niagen Bioscience to maintain trust and credibility among consumers and partners.
The company serves a diverse customer base that includes individual consumers purchasing Tru Niagen, manufacturers of dietary supplements and foods, compounding pharmacies, and research laboratories across various industries. Notably, A. S. Watson Group accounted for a significant portion of sales in 2024, while no single customer exceeded 10% of revenue in 2025. The company also works with a network of international distributors to expand its reach in Asia, Europe, and North America. By catering to both end consumers and business clients, Niagen Bioscience creates multiple avenues for growth.
Sectors:Consumer Staples·Basic MaterialsSector rationaleThe company's primary revenue driver is the sale of Tru Niagen, a finished dietary supplement sold directly to consumers and through retail distributors, which falls under the Personal Care Products or Household Products categories of Consumer Staples. A secondary sector of Basic Materials is justified because the company also operates a substantial Ingredients segment that sells Niagen as a raw material (food and pharmaceutical grade) to other manufacturers, fitting the Specialty Chemicals profile.Industries:Personal Care ProductsPersonal Care ProductsPrimaryThe company develops and markets Tru Niagen, a finished dietary supplement sold directly to consumers and through retail distributors to support health and longevity. This aligns with the S-11 category for nutritional supplements and wellness products sold over the counter.Specialty ChemicalsSpecialty ChemicalsSecondaryThe company produces and sells Niagen as a proprietary food-grade and pharmaceutical-grade ingredient to manufacturers of dietary supplements and foods. This constitutes the sale of a formulated specialty chemical/ingredient for specific applications.Classified using BQ-MICSCIK: 0001386570
Bull & bear
Investment Thesis
▲ Bull case
Niagen Bioscience Inc's leadership in NAD+ science, validated by the USP dietary supplement ingredient monograph for NIAGEN, creates a significant and sustainable competitive moat that the market is underestimating, as it establishes a global benchmark for purity and quality unmatched by NMN competitors, directly supporting premium pricing power and brand trust in an increasingly crowded longevity supplement space where scientific credibility is becoming a key differentiator for consumer choice and partner selection.
The early success of Niagen NanoCloud and Niagen Plus at-home injection kit, despite minimal marketing spend, reveals untapped demand in adjacent high-growth markets like premium skincare and direct-to-consumer telehealth therapeutics, where the company can leverage its scientific reputation and existing customer base to expand margins and reduce reliance on volatile ingredient sales, with NanoCloud already nearly sold out post-pilot and strong early adoption signaling a potential multi-year runway for product-line expansion beyond core TRU NIAGEN.
Strategic progress in pharmaceutical applications, particularly the preclinical work for orphan indications like ataxia telangiectasia and the growing body of evidence supporting tissue-specific NAD+ augmentation via IV/injection pathways, positions Niagen Bioscience Inc to capture long-term value from high-margin therapeutic opportunities that are currently not reflected in near-term financial models, especially as emerging research suggests synergistic effects with exercise and GLP-1 agonists, opening doors for combination therapies and new indications that could transform the company from a supplement player to a niche pharmaceutical innovator.
Niagen Bioscience Inc's leadership in NAD+ science, validated by the USP dietary supplement ingredient monograph for NIAGEN, creates a significant and sustainable competitive moat that the market is underestimating, as it establishes a global benchmark for purity and quality unmatched by NMN competitors, directly supporting premium pricing power and brand trust in an increasingly crowded longevity supplement space where scientific credibility is becoming a key differentiator for consumer choice and partner selection.
The early success of Niagen NanoCloud and Niagen Plus at-home injection kit, despite minimal marketing spend, reveals untapped demand in adjacent high-growth markets like premium skincare and direct-to-consumer telehealth therapeutics, where the company can leverage its scientific reputation and existing customer base to expand margins and reduce reliance on volatile ingredient sales, with NanoCloud already nearly sold out post-pilot and strong early adoption signaling a potential multi-year runway for product-line expansion beyond core TRU NIAGEN.
Strategic progress in pharmaceutical applications, particularly the preclinical work for orphan indications like ataxia telangiectasia and the growing body of evidence supporting tissue-specific NAD+ augmentation via IV/injection pathways, positions Niagen Bioscience Inc to capture long-term value from high-margin therapeutic opportunities that are currently not reflected in near-term financial models, especially as emerging research suggests synergistic effects with exercise and GLP-1 agonists, opening doors for combination therapies and new indications that could transform the company from a supplement player to a niche pharmaceutical innovator.
Niagen Bioscience Inc faces intensifying and underappreciated competitive pressure from the explosion of low-cost NMN products on Amazon and other platforms, which management acknowledged is increasing customer acquisition costs and hindering new-to-brand growth in the core TRU NIAGEN business, a trend that could persist despite skepticism about NMN's long-term viability due to the immediate impact on price-sensitive consumers and the difficulty of overcoming entrenched marketplace dynamics once scale is achieved by competitors.
The company's reliance on a limited number of third-party suppliers for pharmaceutical-grade Niagen, particularly for its IV and injectable products, creates a critical operational vulnerability highlighted by the current inability to serve the California market due to Wells Pharmacy's licensing constraints, a constraint that could recur with other 503B facilities and limit geographic scalability of high-margin telehealth and clinic-based offerings, undermining the growth narrative around Niagen Plus and NanoCloud commercialization.
Rising operating expenses, driven by increased selling and marketing investments to combat NMN competition and support new product launches, coupled with a revised but still elevated outlook for general and administrative costs, are eroding margin expansion potential and converting what should be operational leverage into a drag on profitability, as evidenced by the decline in adjusted EBITDA year-over-year despite net income growth, signaling that top-line growth may not translate to sustainable cash flow generation without stricter cost discipline.
Niagen Bioscience Inc faces intensifying and underappreciated competitive pressure from the explosion of low-cost NMN products on Amazon and other platforms, which management acknowledged is increasing customer acquisition costs and hindering new-to-brand growth in the core TRU NIAGEN business, a trend that could persist despite skepticism about NMN's long-term viability due to the immediate impact on price-sensitive consumers and the difficulty of overcoming entrenched marketplace dynamics once scale is achieved by competitors.
The company's reliance on a limited number of third-party suppliers for pharmaceutical-grade Niagen, particularly for its IV and injectable products, creates a critical operational vulnerability highlighted by the current inability to serve the California market due to Wells Pharmacy's licensing constraints, a constraint that could recur with other 503B facilities and limit geographic scalability of high-margin telehealth and clinic-based offerings, undermining the growth narrative around Niagen Plus and NanoCloud commercialization.
Rising operating expenses, driven by increased selling and marketing investments to combat NMN competition and support new product launches, coupled with a revised but still elevated outlook for general and administrative costs, are eroding margin expansion potential and converting what should be operational leverage into a drag on profitability, as evidenced by the decline in adjusted EBITDA year-over-year despite net income growth, signaling that top-line growth may not translate to sustainable cash flow generation without stricter cost discipline.